See more : Jaxsta Limited (JAXAF) Income Statement Analysis – Financial Results
Complete financial analysis of Opthea Limited (OPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Opthea Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The New Home Company Inc. (NWHM) Income Statement Analysis – Financial Results
- Ormat Technologies, Inc. (HNM.DE) Income Statement Analysis – Financial Results
- Beijing ConST Instruments Technology Inc. (300445.SZ) Income Statement Analysis – Financial Results
- Henan Rebecca Hair Products Co., Ltd. (600439.SS) Income Statement Analysis – Financial Results
- property technologies Inc. (5527.T) Income Statement Analysis – Financial Results
Opthea Limited (OPT)
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124.67K | 161.16K | 125.05K | 91.98K | 145.90K | 112.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | 0.00 | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 250.47K | 232.47K | 571.98K | 517.26K | 273.94K | 28.66K | 26.61K | 30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 27.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 124.67K | -89.31K | -107.42K | -480.00K | -371.37K | -161.45K | -28.66K | -26.61K | -30.79K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 14.35K | 19.13K | 0.00 | 13.34K | 12.24K | 0.00 | 9.57K | 0.00 | -27.35K | 2.94B | 192.74K | 240.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% | -143.51% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 176.33M | 181.56M | 108.46M | 34.71M | 17.48M | 31.35M | 24.89M | 4.84M | 3.58M | 4.28M | 3.40M | 3.14M | 3.68M | 7.02M | 3.65M | 3.62M | 3.27M | 2.67M | 1.20M | 533.75K | 349.78K | 106.50K | 144.69K | 553.00K | 186.15K | 358.33K | 600.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.67K | 0.00 | 0.00 |
| General & Administrative | 15.49M | 19.27M | 16.30M | 11.88M | 6.61M | 5.09M | 2.70M | 3.25M | 2.86M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 22.63M | 8.52M | 6.54M | 43.14K | 108.90K | 2.29M | 629.16K | 613.02K | 359.30K | 477.17K | 538.63K | 467.15K | 713.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.49M | 41.90M | 24.83M | 18.42M | 6.65M | 5.20M | 4.99M | 5.03M | 4.47M | 2.36M | 2.65M | 3.11M | 3.58M | 4.36M | 4.57M | 3.77M | 3.44M | 3.39M | 2.04M | 1.65M | 1.34M | 1.32M | 1.16M | 1.88M | 320.84K | 332.21K | 0.00 | 252.31K | 204.75K | 132.10K | 113.26K | 74.82K | 43.33K | 59.82K | 0.00 | 0.00 |
| Other Expenses | 152.46K | 12.30M | 0.00 | 0.00 | 0.00 | 56.76K | 2.03K | 1.23K | 6.23K | 48.00K | 183.04K | 29.55K | 199.06K | 78.32K | 2.12K | 106.79K | 5.76K | 130.52K | 50.38K | 22.90M | 5.33M | 11.79K | 96.84K | 875.00K | 1.59M | 2.79M | 73.54K | 81.79K | 11.03K | 47.58K | 432.57K | 9.00K | 10.00K | 20.00K | 10.00K | 4.53K |
| Operating Expenses | 191.97M | 223.46M | 133.29M | 53.13M | 24.71M | 36.27M | 29.88M | 9.87M | 8.05M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 520.09K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Cost & Expenses | 191.97M | 223.61M | 133.40M | 53.27M | 25.23M | 36.54M | 29.91M | 9.90M | 8.08M | 6.80M | 6.59M | 6.88M | 8.90M | 12.27M | 8.68M | 8.46M | 8.26M | 14.38M | 3.55M | 2.32M | 1.80M | 2.94M | 1.32M | 12.76K | 547.44K | 14.89M | 13.11K | 6.78K | 208.69K | 135.65K | 114.72K | 74.82K | 44.07K | 68.25K | 7.93K | -7.55K |
| Interest Income | 3.39M | 4.80M | 324.70K | 498.70K | 696.18K | 755.78K | 735.70K | 384.35K | 325.57K | 324.56K | 258.85K | 530.99K | 998.39K | 1.48M | 1.39M | 1.86M | 3.12M | 1.73M | 815.55K | 1.14M | 617.15K | 569.19K | 579.33K | 1.59M | 326.53K | 106.45K | 72.52K | 158.75K | 82.69K | 54.69K | 36.54K | 7.35K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.26M | 20.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 576.11K | 0.00 | 391.82K | 0.00 | 0.00 | 71.87K | 179.45K | 0.00 | 0.00 | 1.13K | 8.16K | 0.00 | 0.00 | 1.98M | 1.40M | 787.50 | 1.42K | 1.46K | 668.00 | 2.24K | 5.37K | 3.97K | 7.55K | |
| Depreciation & Amortization | 103.03K | 150.49K | 108.08K | 143.00K | 144.02K | 33.09K | 28.66K | 26.61K | 30.79K | 29.58K | 35.98K | 24.95K | 29.25K | 30.02K | 24.30K | 27.49K | 29.98K | 25.42K | 13.69K | 23.86K | 26.59K | 0.00 | 16.33K | 12.76K | 13.10K | 14.89M | 13.11K | 6.78K | 3.94K | 3.55K | 1.46K | -273.21K | 747.00 | 766.90 | 7.93K | -7.55K |
| EBITDA | -200.02M | -223.30M | -133.16M | -52.85M | -24.92M | -36.64M | -29.74M | -9.80M | -7.72M | -8.08M | -6.81M | -6.54M | -7.45M | -11.05M | -9.63M | -9.24M | -8.22M | -37.88M | -4.41M | 21.89M | -2.54M | -2.94M | -3.22M | -807.30K | -534.34K | 2.94B | 192.74K | 240.51K | -967.05K | -522.00K | -78.92K | -348.03K | -72.46K | -163.35K | -627.42K | -511.89K |
| EBITDA Ratio | -160,443.72% | -138,554.61% | -106,489.56% | -57,660.19% | -16,914.89% | -32,565.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -87,982.98% | -198,006.39% | 0.00% | 132,162.03% | -14,580.37% | 0.00% | -33,605.88% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -191.84M | -223.45M | -133.27M | -53.18M | -24.70M | -36.67M | -29.91M | -9.90M | -8.08M | -7.00M | -6.29M | -7.25M | -8.95M | -11.23M | -10.17M | -7.57M | -12.66M | -37.90M | -3.92M | 17.61M | -1.81M | -2.97M | -3.25M | -833.02K | -547.44K | -741.67K | -1.23M | -1.06M | -970.99K | -525.55K | -80.38K | -74.82K | -73.21K | -164.12K | -635.35K | -504.34K |
| Operating Income Ratio | -153,885.37% | -138,647.99% | -106,575.99% | -57,815.66% | -16,929.71% | -32,595.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -88,191.87% | -198,139.25% | 0.00% | 131,983.17% | -14,797.71% | 0.00% | -33,943.71% | 0.00% | 0.00% | -0.03% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -37.81M | -70.67M | -3.41M | -14.23M | 310.76K | 1.03M | 2.98M | 535.06K | -16.02K | 2.24M | 1.16M | 958.26K | 1.72M | 855.19K | 1.17M | -1.70M | 7.18M | 24.55M | -661.28K | -1.01M | 5.87M | 495.02K | -1.92M | -8.17K | 1.28M | 2.32M | -771.54K | -1.04M | 81.90K | 53.27K | 35.07K | -266.53K | 12.70K | 25.31K | 142.78K | 93.62K |
| Income Before Tax | -229.65M | -220.69M | -136.68M | -67.41M | -24.39M | -35.55M | -28.92M | -9.36M | -8.10M | -6.23M | -6.45M | -5.99M | -7.48M | -11.80M | -5.81M | -7.97M | -1.07M | 10.19M | -4.58M | 16.60M | 4.06M | -2.45M | -3.23M | -828.22K | 730.42K | 1.58M | -1.23M | -1.06M | -889.09K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Income Before Tax Ratio | -184,215.67% | -136,936.62% | -109,300.18% | -73,285.73% | -16,716.71% | -31,598.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,445.89% | 53,289.60% | 0.00% | 124,394.23% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 0.05% | -638.09% | -439.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -9.41M | -8.81M | -8.69M | -6.62M | 8.27M | 14.64M | -12.02M | -3.17M | -1.57M | -2.09M | -2.69M | -1.42M | -2.46M | -831.43K | 93.06K | 37.02K | 1.12M | 4.85M | 252.37K | 2.79K | -5.87M | -83.76K | 85.58 | -39.80K | -1.28M | 2.37M | -1.98M | -1.40M | -1.13M | -665.00K | -62.00K | -511.00K | -81.00K | -181.00K | -621.00K | -544.00K |
| Net Income | -220.24M | -211.88M | -127.99M | -60.79M | -16.12M | -20.91M | -16.90M | -6.19M | -6.51M | -4.07M | -3.76M | -4.34M | -4.95M | -10.97M | -5.91M | -8.00M | -1.10M | 9.50M | -4.80M | 16.60M | 4.06M | -2.36M | -3.23M | -801.17K | 730.42K | 1.58B | -1.23M | -1.05M | -857.59K | -472.28K | -45.30K | -341.35K | -60.51K | -138.81K | -492.58K | -410.72K |
| Net Income Ratio | -176,665.73% | -131,469.80% | -102,353.69% | -66,087.58% | -11,047.04% | -18,587.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7,652.13% | 49,675.59% | 0.00% | 124,404.80% | 33,158.07% | 0.00% | -33,788.24% | 0.00% | 0.00% | 53.84% | -638.09% | -438.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -2.77 | -0.45 | -0.34 | -0.18 | -0.06 | -0.09 | -0.07 | -0.03 | -0.04 | -0.04 | -0.07 | -0.09 | -0.10 | -0.23 | -0.13 | -0.18 | -0.03 | 0.23 | -0.12 | 0.40 | 0.10 | -0.06 | -0.08 | -0.02 | 0.02 | 48.81 | -0.03 | -0.03 | -0.03 | -0.02 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 79.78M | 469.56M | 372.94M | 339.92M | 260.50M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 48.57M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
| Weighted Avg Shares Out (Dil) | 79.78M | 469.56M | 372.94M | 339.92M | 260.80M | 232.80M | 232.17M | 185.69M | 172.99M | 115.73M | 52.78M | 49.71M | 47.61M | 47.32M | 46.29M | 45.65M | 41.05M | 41.32M | 41.05M | 41.05M | 41.10M | 42.24M | 42.20M | 41.83M | 33.62M | 32.42M | 35.49M | 36.12M | 27.17M | 26.07M | 25.37M | 24.51M | 22.31M | 232.80M | 232.80M | 232.80M |
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
MELBOURNE, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that OPT-302, the Company's first-in-class VEGF-C/D “trap” inhibitor will be...
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today the resignation of Dr. Joel Naor, Chief Medical Officer (CMO),...
Opthea to Present at the Jefferies 2023 Healthcare Conference
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will...
Opthea To Present at the JMP Securities Life Sciences Conference
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Timothy E. Morris, the Company's Chief Financial Officer will...
Opthea To Present at SVB Leerink Global Biopharma Conference
MELBOURNE, Australia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will...
Opthea To Present at Sequire Biotechnology Conference
MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company's Chief Executive Officer will...
Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD
MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an “Ask the Expert” conference call...
Opthea to Present at the FLORetina 2022 Congress
MELBOURNE, Australia, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce a podium talk will be presented at the annual FLORetina congress,...
Optiva Inc. (RKNEF) Q3 2022 Earnings Call Transcript
Optiva Inc. (OTCPK:RKNEF) Q3 2022 Results Conference Call November 9, 2022 8:30 AM ET Company Participants Ali Mahdavi - Investor Relations John Giere - President and CEO Dinesh Sharma - VP of Finance Conference Call Participants Todd Coupland - CIBC...
Opthea to Present at Jefferies London Healthcare Conference
MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced that Chief Executive Officer Dr. Megan Baldwin will present at...
Source: https://incomestatements.info
Category: Stock Reports